首页> 外文期刊>Frontiers in Cell and Developmental Biology >A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma
【24h】

A Novel Immune-Related Prognostic Model for Response to Immunotherapy and Survival in Patients With Lung Adenocarcinoma

机译:一种新的免疫相关预后模型,用于反应肺腺癌患者免疫疗法和存活

获取原文
获取外文期刊封面目录资料

摘要

Lung adenocarcinoma is one of the most malignant diseases worldwide. The immune checkpoint inhibitors targeting PD-1 and PD-L1 has changed the paradigm of lung cancer treatment, however, there are still patients who are resistant. Further exploration of the immune infiltration status of LUAD is necessary for better clinical management. In our study, the CIBERSORT method was used to calculate 22 immune cells in LUAD in TCGA. We clustered LUAD based on immune infiltration status by consensus clustering. The differentially expressed genes (DEGs) between cold and hot tumor group were identified. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were performed. Last, we constructed a Cox regression model and validated. We found that the infiltration of M0 macrophage cells and follicular helper T cells predicted an unfavorable overall survival of patients. Consensus clustering of 22 immune cells identified 5 clusters with different patterns of immune cells infiltration, stromal cells infiltration, and tumor purity. Based on the immune scores we classified these 5 clusters into hot tumors and cold tumors, which are different in transcription profiles. Hot tumors are enriched in cytokine-cytokine receptor interaction, while cold tumors are enriched in metabolic pathways. Based on the hub genes and prognostic related genes, we developed a cox regression model to predict the overall survival of patients with LUAD and validated in other 3 datasets. We developed an immune-related signature that can predict the prognosis of patients which might facilitate the clinical application of immunotherapy in LUAD.
机译:肺腺癌是全世界最恶劣的疾病之一。靶向PD-1和PD-L1的免疫检查点抑制剂改变了肺癌治疗的范例,然而,仍有耐受性的患者。进一步探索管道的免疫渗透状态对于更好的临床管理是必要的。在我们的研究中,Cibersort方法用于在TCGA的管道中计算22例免疫细胞。我们根据共识聚类,基于免疫渗透状态集成了路提。鉴定了冷和热肿瘤基团之间的差异表达基因(DEGS)。进行基因本体(GO)和京都基因和基因组(KEGG)富集分析。最后,我们构建了COX回归模型并验证。我们发现M0巨噬细胞和卵泡辅助T细胞的浸润预测了患者的不利整体存活。 22个免疫细胞的共有聚类鉴定了具有不同免疫细胞浸润的不同模式,基质细胞浸润和肿瘤纯度的5种簇。基于免疫分数,我们将这些5种簇分为热肿瘤和冷肿瘤,在转录型材中不同。热肿瘤富含细胞因子 - 细胞因子受体相互作用,而冷肿瘤富集在代谢途径中。基于集线器基因和预后相关基因,我们开发了一种COX回归模型,以预测拉拉患者的整体存活并在其他3个数据集中验证。我们开发了一种免疫相关签名,可以预测可能促进拉德免疫疗法临床应用的患者的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号